Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Genotype 1 or 4 chronic HCV infection~* Have received a kidney transplant more than 6 months before the Baseline visit~* Cirrhosis determination~* Screening laboratory parameters within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Key Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain -resolved skin cancers)~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol~* Planned or anticipated second kidney transplant~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 12 wk (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC for 12 weeks.
- LDV/SOF 24 wk (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).